Niraparib and Dostarlimab in HRD Solid Tumors
NCT04983745
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Homologous Recombination Deficient Solid Tumors
Interventions
DRUG:
Combination drug
Sponsor
West Cancer Center